AIM
LGND icon

Aigen Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Aigen Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,808
Closed -$205K – 912
2024
Q1 		$205K Buy
+2,808
New +$207K 0.04% 539
2020
Q1 		– Sell
-16,740
Closed -$1.09M – 1423
2019
Q4 		$1.09M Buy
+16,740
New +$1.12M 0.18% 164

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Aigen Investment Management's LGND Position: Q2 2024 in Review

Aigen Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 2,808 shares — an estimated $205K sold.

Aigen Investment Management first reported a position in LGND in Q4 2019 and held it in 2 quarters. The position peaked at $1.09M in Q4 2019. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Aigen Investment Management reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Aigen Investment Management sold 2,808 Ligand Pharmaceuticals shares in Q2 2024, an estimated $205K.
  • Aigen Investment Management first reported a position in Ligand Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Aigen Investment Management's Ligand Pharmaceuticals position peaked at $1.09M in Q4 2019.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Aigen Investment Management's 13F filing for Q2 2024, filed 9 Aug 2024.